Please ensure Javascript is enabled for purposes of website accessibility

Why Illumina Shares Are Tanking 18% Pre-Market

By Todd Campbell - Apr 19, 2016 at 8:35AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Lower-than-hoped first quarter performance is weighing down shares.


What: After issuing preliminary revenue for the first quarter that was below industry watcher's targets, shares of Illumina (ILMN 1.12%) are indicated to open lower by 18% today as of 8:30 a.m. EST.

So what: The maker of machines used in sequencing genomes reports that first quarter revenue will likely be $572 million. That figure is up 6% year-over-year, but is 4% lower than analysts' projections. Illumina's management expects that sales will accelerate this year by 12% in spite of the first quarter results. The company will report its complete audited results on May 3. 

In addition to reporting lackluster sales, CEO Jay Flatley also indicated that while they don't have a precise EPS number to release yet, he does believe that the final EPS number will be shy of analysts' forecasts too.

"Gross margins will be lower than normal due to the reduction in sales volume, but that difference is expected to be partially offset by lower operating expenses and stock-based compensation," said Flatley on Illumina's conference call after the closing bell yesterday. Overall, Flatley expects "non-GAAP EPS to be below the current consensus expectation, consistent with the revenue shortfall."

A big reason behind the sales miss this quarter appears to have been sluggish demand in Europe. Sales in the Americas and Asia-Pacific regions remain on track with previously issued guidance for mid-teens growth, but European shipment growth in the low- to mid-single digits is creating a big headwind to global growth rates.

Now what: A sales miss is never a good thing, especially considering that competitors, including Pacific Biosciences (PACB 1.96%), are mounting their most significant threat yet.

Last fall, Pacific Biosciences released its aptly named Sequel machine, offering better performance and longer data reads at a lower price point than Illumina's solutions. Exiting Pacific Biosciences' fourth quarter, management reported that they had received 49 orders for the Sequel, including orders for 10 machines that they installed at customer sites in December. For comparison, the company recorded 40 orders for the RS II in the entirety of 2014.

It's not clear whether or not Illumina's disappointing results are due to competitive launches or a weak Europe. Investors will know more when Pacific Biosciences reports its first quarter financials on April 21.

Regardless, Illumina remains the biggest player in gene sequencing by far. Innovation that's leading to significant adoption of personalized medicine suggests that the company's got plenty of opportunity to get back on track to double digit growth in the future. If so, then this sell-off may be the perfect opportunity to add this stock to healthcare portfolios.


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Illumina, Inc. Stock Quote
Illumina, Inc.
$243.44 (1.12%) $2.69
Pacific Biosciences of California, Inc. Stock Quote
Pacific Biosciences of California, Inc.
$5.71 (1.96%) $0.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.